Isolated reoperative tricuspid valve replacement is one of the highest risk operations classified in the Society of Thoracic Surgeons registry, particularly in the setting of preexisting right ventricular dysfunction. Transcatheter tricuspid valve-in-valve implantation represents an attractive alternative to redo surgery in patients with tricuspid bioprosthetic valve degeneration who are considered high-risk or unsuitable surgical candidates. In this review article, the authors discuss the emergence of transcatheter tricuspid valve-in-valve therapy, preprocedural echocardiographic assessment of tricuspid bioprosthetic valve dysfunction, periprocedural imaging required for tricuspid valve-in-valve implantation, and postprocedural assessment of tricuspid transcatheter device function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.echo.2017.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Same-Day Discharge After Uncomplicated Transcatheter Tricuspid Valve-In-Valve Implantation.
Catheter Cardiovasc Interv
January 2025
Department of Pediatric and Adolescent Medicine/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.
Background: Tricuspid valve-in-valve (TVIV) implantation has traditionally included post-procedure overnight in-hospital observation with next-day discharge. Recently, our practice has shifted toward same-day discharge for most patients after vascular access site hemostasis and adequate recovery from anesthesia. However, data on the safety of this approach remains scarce.
View Article and Find Full Text PDFKey Imaging Factors for Transcatheter Management of Tricuspid Regurgitation: Device and Patient Selection.
J Clin Med
October 2024
IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, 20089 Milano, Italy.
The growing awareness of tricuspid regurgitation (TR) and the fast-expanding array of devices aiming to percutaneously repair or replace the tricuspid valve have underscored the central role of multi-modality imaging in comprehensively assessing the anatomical and functional characteristics of TR. Accurate phenotyping of TR, the right heart, and pulmonary vasculature via echocardiography, computed tomography, and, occasionally, cardiovascular magnetic resonance and right heart catheterization is deemed crucial in choosing the most suitable treatment strategy for each patient and achieving procedural success. In the first part of the present review, key imaging factors for patient selection will be discussed.
View Article and Find Full Text PDFThe novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications.
Rev Esp Cardiol (Engl Ed)
October 2024
Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario, Valladolid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. Electronic address:
Article Synopsis
- Myval technology is a new balloon-expandable option for treating heart valve issues, emerging after the established Edwards system, and its usage is increasing despite some debated points.
- A thorough literature review covering studies from December 2016 to May 2024 showed Myval to be effective for native aortic stenosis with low mortality and complication rates, and its performance compares favorably to other devices.
- The findings also indicate that Myval is safe for various off-label uses, achieving high success rates across different heart valve procedures, although more extensive studies are needed to confirm these results.
Pulmonary valve replacement-A 10-year single-center surgical experience in ACHD patients.
PLoS One
October 2024
Department of Cardiothoracic Surgery, University Hospital Muenster, Muenster, Germany.
Article Synopsis
- This study reviews surgical outcomes of pulmonary valve replacements in adults with congenital heart disease, specifically focusing on patients who underwent this procedure over the past decade.
- A total of 79 patients were analyzed, with the majority having Tetralogy of Fallot, and the surgery involved removing the old valve and using a larger bioprosthesis, often alongside other surgeries like tricuspid valve repairs.
- Results showed effective post-operative outcomes, with no severe valve insufficiency noted and improved heart function metrics in MRI studies, confirming sPVR as a safe and effective treatment option with a low mortality rate (5.1%).
Background: Actual expansion of a transcatheter heart valve (THV) might differ from nominal, particularly during nonaortic valve-in-valve for a degenerated bioprosthetic surgical heart valve (SHV). This pilot study compared THV expansion measured using large-field-of-view intravascular ultrasound (IVUS) vs. multi-slice computed tomography (MSCT) and assessed the correlation between THV dimensions and transvalvular gradients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!